Olverembatinib Shows Promise Against Resistance in Leukemia Treatments: Insights from a Recent Clinical Study
Olverembatinib, a third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI), has recently gained attention for its potential in effectively combating treatment resistance in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph⁺ ALL). This has been highlighted in a multicenter clinical trial published in the November 2024 issue of JAMA Oncology, one of the leading journals in the oncology field, boasting a significant impact factor of 28.4.
The clinical trial (NCT04260022) involved 80 patients, all heavily pretreated with an average of over four prior TKIs. The trial aimed to explore the effectiveness of olverembatinib against the common barriers to treatment caused by resistance and intolerance related to existing TKIs such as ponatinib and asciminib. Clear results showcased that about 61% of patients with CML achieved a complete cytogenetic response (CCyR), while around 42% reached a major molecular response (MMR), regardless of whether they harbored the T315I mutation associated with resistance to first- and second-generation TKIs.
Among those who had previously failed treatment with ponatinib, an impressive 58% attained CCyR and 37% achieved MMR. Similar results were seen in patients resistant to asciminib, with 50% and 33% respectively meeting the CCyR and MMR criteria, revealing olverembatinib's effectiveness in monosomic mutations that often complicate treatment plans.
Moreover, the study confirmed olverembatinib's safety profile, reporting mainly mild to moderate treatment-related adverse events such as elevated creatine phosphokinase levels and thrombocytopenia, with no fatalities related to the treatment. Arterial occlusive events (AOEs), known to complicate TKI therapies, were infrequent and predominantly mild.
Ascentage Pharma, the biotechnology firm behind olverembatinib, expressed excitement over the drug’s progress, stating it exemplifies their commitment to addressing significant unmet medical needs in hematologic malignancies. Dr. Yifan Zhai, Ascentage's Chief Medical Officer, emphasized that ongoing development programs aim to provide additional treatment options for patients facing serious challenges with current therapies.
The findings from this trial have garnered global attention, presented at numerous high-profile oncological congresses including the European Hematology Association Congress and the Society of Hematologic Oncology Annual Meeting. As the results gain traction, an impending phase III registrational trial (POLARIS-2) is underway, which may further solidify olverembatinib's position as a significant contender in this therapeutic landscape.
According to principal investigator Dr. Elias Jabbour, the broad mutational coverage of olverembatinib positions it distinctively against complex mutational profiles, potentially providing enhanced responses compared to other TKIs recently approved.
In summary, the publication of these results represents a pivotal moment not only for ascertaining the efficacy of olverembatinib but also for advancing treatment options for patients whose leukemia has become resistant to traditional therapies. Moving forward, collaborations with partners such as Takeda may expand access to this promising therapy, potentially altering the treatment landscape for patients battling CML or Ph⁺ ALL worldwide.
Olverembatinib is currently approved for use in China but remains investigational in other countries. Its clinical journey will continue to be watched closely as more data emerges from ongoing and future studies.
The clinical trial (NCT04260022) involved 80 patients, all heavily pretreated with an average of over four prior TKIs. The trial aimed to explore the effectiveness of olverembatinib against the common barriers to treatment caused by resistance and intolerance related to existing TKIs such as ponatinib and asciminib. Clear results showcased that about 61% of patients with CML achieved a complete cytogenetic response (CCyR), while around 42% reached a major molecular response (MMR), regardless of whether they harbored the T315I mutation associated with resistance to first- and second-generation TKIs.
Among those who had previously failed treatment with ponatinib, an impressive 58% attained CCyR and 37% achieved MMR. Similar results were seen in patients resistant to asciminib, with 50% and 33% respectively meeting the CCyR and MMR criteria, revealing olverembatinib's effectiveness in monosomic mutations that often complicate treatment plans.
Moreover, the study confirmed olverembatinib's safety profile, reporting mainly mild to moderate treatment-related adverse events such as elevated creatine phosphokinase levels and thrombocytopenia, with no fatalities related to the treatment. Arterial occlusive events (AOEs), known to complicate TKI therapies, were infrequent and predominantly mild.
Ascentage Pharma, the biotechnology firm behind olverembatinib, expressed excitement over the drug’s progress, stating it exemplifies their commitment to addressing significant unmet medical needs in hematologic malignancies. Dr. Yifan Zhai, Ascentage's Chief Medical Officer, emphasized that ongoing development programs aim to provide additional treatment options for patients facing serious challenges with current therapies.
The findings from this trial have garnered global attention, presented at numerous high-profile oncological congresses including the European Hematology Association Congress and the Society of Hematologic Oncology Annual Meeting. As the results gain traction, an impending phase III registrational trial (POLARIS-2) is underway, which may further solidify olverembatinib's position as a significant contender in this therapeutic landscape.
According to principal investigator Dr. Elias Jabbour, the broad mutational coverage of olverembatinib positions it distinctively against complex mutational profiles, potentially providing enhanced responses compared to other TKIs recently approved.
In summary, the publication of these results represents a pivotal moment not only for ascertaining the efficacy of olverembatinib but also for advancing treatment options for patients whose leukemia has become resistant to traditional therapies. Moving forward, collaborations with partners such as Takeda may expand access to this promising therapy, potentially altering the treatment landscape for patients battling CML or Ph⁺ ALL worldwide.
Olverembatinib is currently approved for use in China but remains investigational in other countries. Its clinical journey will continue to be watched closely as more data emerges from ongoing and future studies.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.